Ocular photodynamic therapy
This article was originally published in The Gray Sheet
Coverage review initiated by HCFA July 26 could lead to a national Medicare coverage decision for QLT PhotoTherapeutics' Visudyne (verteporfin) to treat age-related macular degeneration (AMD). Marketed by Novartis' Ciba Vision eye care unit, Visudyne is an intravenous photosensitizing drug that is activated by a laser. Coherent, Inc. and Zeiss Humphrey Systems have competed in the AMD laser market since Visudyne's FDA approval April 13
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.